Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.

about

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.

Item

http://www.wikidata.org/entity/Q38749391

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Variability in and predictors ...... ily and exenatide once weekly.

@en

type

Item

label

Variability in and predictors ...... ily and exenatide once weekly.

@en

prefLabel

Variability in and predictors ...... ily and exenatide once weekly.

@en

P1476

Variability in and predictors ...... aily and exenatide once weekly

@en

P2093

Baptist Gallwitz

http://www.w3.org/2001/XMLSchema#string

Elise Hardy

http://www.w3.org/2001/XMLSchema#string

Guntram Schernthaner

http://www.w3.org/2001/XMLSchema#string

Jenny Han

http://www.w3.org/2001/XMLSchema#string

P2860

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes

P304

1793-1797

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.13022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan E Shaw

P577

2017-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28573708

http://www.w3.org/2001/XMLSchema#string

P932

5697639

http://www.w3.org/2001/XMLSchema#string